Structural basis of inhibitor selectivity in MAP kinases

Structure

Volumn 6, Issue 9, 1998, Pages 1117-1128

  Wang, Zhulun ^a   Canagarajah, Bertram J ^a   Boehm, Jeffrey C ^b   Kassisà, Skouki ^b   Cobb, Melanie H ^a   Young, Peter R ^b   Abdel Meguid, Sherin ^b   Adams, Jerry L ^b   Goldsmith, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CSAID(TM); ERK2; Inhibitor; MAP kinase; Olomoucine; p38

Indexed keywords

EID: 0032530336     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(98)00113-0     Document Type: Article

References (59)

1. Robbins, D.J., Zhen, E., Cheng, M., Xu, S., Ebert, D. & Cobb, M.H. (1994). MAP kinases ERK1 and ERK2: pleiotropic enzymes in a ubiquitous signaling network. Adv. Cancer Res. 63, 93-116.
2. Cobb, M.H. & Goldsmith, E.J. (1995). How MAP kinases are regulated. J. Biol. Chem. 270, 14843-14846.
3. Cuenda, A., et al., & Lee, J.C. (1995). SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233.
4. Seger, R. & Krebs, E.G. (1995). The MAPK signaling cascade. FASEB J. 9, 726-735.
5. Chen, Y.-R., Wang, X., Templeton, D., Davis, R.J. & Tan, T.-H. (1996). The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. J. Biol. Chem. 271, 31929-31936.
6. Cano, E. & Mahadevan, L.C. (1995). Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20, 117-122.
7. Lee, J.C., et al. & Young, P.R. (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
8. Sivaraman, V.S., Wang, H.-Y., Nuovo, G.J. & Malbon, C.C. (1997). Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478-1483.
9. Raitano, A.B., Halpern, J.R., Hambuch, T.M. & Sawyers, C.L. (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl Acad. Sci. USA 92, 11746-11750.
10. Boulton, T.G., et al., & Cobb, M.H. (1990). An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249, 64-67.
11. Boulton, T.G., et al., & Yancopoulos, G.D. (1991). ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675.
12. Dérijard, B., et al., & Davis, R.J (1994). JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-1037.
13. Kyriakis, J.M., et al., & Woodgett, J.R. (1994). The stress-activated protein kinase subfamily of c-jun kinases. Nature 369, 156-160.
14. Kallunki, T., et al., & Karin, M. (1994). JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8, 2996-3007.
15. Han, J., Lee, J.-D., Bibbs, L. & Ulevitch, R.J. (1994). A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811.
16. Rouse, J., et al., & Nebreda, A.R. (1994). A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027-1037.
17. Freshney, N.W., et al., & Saklatvala, J. (1994). Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039-1049.
18. Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M. & Mumby, M. (1993). The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the MAP kinase pathway and induces cell proliferation. Cell 75, 887-897.
19. Raingeaud, J., et al., & Davis, R.J. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270, 7420-7426.
20. Kyriakis, J.M. & Avruch, J. (1996). Sounding the alarm: Protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 271, 24313-24316.
21. Rosette, C. & Karin, M. (1996). Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274, 1194-1197.
22. Lee, J.C. & Adams, J.L. (1995). Inhibitors of serine/threonine kinases. Curr. Opin Biotechnol. 6, 657-661.
23. Gallagher, T.F., et al., & Adams, J.L. (1997). Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. Lett. 5, 49-64.
24. Badger, A.M., Bradbeer, J.N., Votta, B., Lee, J.C., Adams, J.L. & Griswold, D.E. (1996). Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279, 1453-1461.
25. Young, P.R., et al., & Lee, J.C. (1997). Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272, 12116-12121.
26. Tong, L., et al., & Pargellis, C.A. (1997). A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4, 311-316.
27. Wilson, K.P., et al., & Su, M.S.-S. (1997). The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431.
28. Zhang, F., Strand, A., Robbins, D., Cobb, M.H. & Goldsmith, E.J. (1994). Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367, 704-711.
29. Wang, Z., Harkins, P.C., Ulevitch, R.J., Han, J., Cobb, M.H. & Goldsmith, E.J. (1997). The structure of the mitogen-activated protein kinase P38 at 2.1 resolution. Proc. Natl Acad. Sci. USA 94, 2327-2332.
30. Wilson, K.P., et al., & Su, M.S.-S. (1996). Crystal structure of the p38 mitogen-activated protein kinase. J. Biol. Chem. 271, 27696-27700.
31. Canagarajah, B.J., Khokhlatchev, A., Cobb, M.H. & Goldsmith, E.J. (1997). Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869.
32. Goldsmith, E.J. & Cobb, M.H. (1994). Protein kinases. Curr. Opin. Struct. Biol. 4, 833-840.
33. Vesely, J., et al., & Meijer, L. (1994). Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771-786.
34. Akiyama, T., et al., & Fukami, Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595.
35. Graziani, J., Erikson, E. & Erikson, R.L. (1983). The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur. J. Biochem. 135, 583-589.
36. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. & Saltiel, A.R. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinases kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494.
37. Knighton, D.R., et al., & Sowadski, J.M. (1991). Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-413.
38. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, H.D., Morgan, D.O. & Kim, S.-H. (1993). Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602.
39. Schulze-Gahmen, U., et al., & Kim, S.-H. (1995). Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 22, 378-391.
40. Mohammadi, M., et al., & Schlessinger, J. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-959.
41. Singh, J., Dobrusin, E.M., Fry, D.W., Haske, T., Whitty, A. & McNamara, D.J. (1997). Structure-based design of a potent selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130-1135.
42. De Azevedo, W.F.,Jr., Mueller-Dieckmann, H.-J., Schulze-Gahmen, U., Worland, P.J., Sausville, E. & Kim, S.-H. (1996). Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl Acad. Sci. USA 93, 2735-2740.
43. Baker, E.N. & Hubbard, R.E. (1984). Hydroden bonding in globular proteins. Prog. Biophys. Mol. Biol. 44, 97-179.
44. De Azevedo, W.F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. & Kim, S.-H. (1997). Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-526.
45. Xu, R.-M., Carmel, G., Kuret, J. & Cheng, X. (1996). Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 93, 6308-6313.
46. Mertens, S., Craxton, M. & Goedert, M. (1996). SAP kinase-3, a new member of the family of mammmalian stress-activated protein kinases. FEBS Lett. 383, 273-276.
47. Kumar, S., McDonnell, P.C., Gum, R.J., Hand, A.T., Lee, J.C. & Young, P.R. (1997). Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235, 533-538.
48. Goedert, M., Cuenda, A., Craxton, M., Jakes, R. & Cohen, P. (1997). Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J. 16, 3563-3571.
49. Gum, R.J., et al., & Young, P.R. (1998) Acquistion of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket J. Biol. Chem. 273, 15605-15610.
50. Bossemeyer, D. (1994). The glycine-rich sequence of protein kinases: a multifunctional element. Trends. Biochem. Sci. 19, 201-205.
51. Johnson, L.N., Noble, M.E.M. & Owen, D.J. (1996). Active and inactive protein kinases: Structural basis for regulation. Cell 85, 149-158.
52. Otwinowski, Z. (1993) Oscillation data reduction program. In Proceedings of the CCP4 Study Weekend: Data Collection and Processing. (Sawyer, L., Issacs, N. & Bailey, S.W., eds), pp. 56-62, SERC Daresbury Laboratory, England.
53. Read, R.J. (1986). Improved fourier coefficients for maps using phases from partial structures with errors. Acta Cryst. A 42, 140-149.
54. Collaborative Computational Project, Number 4 (1994). The CCP4 suite: programs for protein crystallography. Acta Cryst. D 50, 760-763.
55. Jones, T.A. and Kjeldgaard, M. (1993). O version 5.9. Uppsala, Sweden, Uppsala University.
56. Brünger, A.T. (1992) In X-PLOR Version 3.1: A System for X-ray Crystallography and NMR, Yale University, Department of Molecular Biophysics, New Haven, CT.
57. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. (1993). Procheck: a program to check the stereochemical quality of protein structures . J. Appl. Cryst. 26, 283-291.
58. Evans, S.V. (1993). SETOR: Hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graph. 11, 134-138.
59. Esnousf, B.M. (1997). An extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15, 133-138.